Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ABLC Clear all
Terminated Phase 3 Interventional

Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant Recipients

NCT00235651
View directory record Official record
Conditions
Lung Transplantation, Lung Diseases
Interventions
Amphotericin B
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2008 · Synced Sep 2, 2026, 4:34 AM EDT
Recruiting Phase 2 Interventional

Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy

NCT07215273
View directory record Official record
Conditions
Invasive Mould Infection
Interventions
EL219, Active Comparator- IV Antifungal (LAmB or voriconazole)
Drug
Lead sponsor
Elion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
7
States / cities
Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 2, 2026, 4:34 AM EDT
Terminated Phase 2 Interventional

Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis

NCT00047827
View directory record Official record
Conditions
Aspergillosis
Interventions
Micafungin, Liposomal Amphotericin B
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Sep 2, 2026, 4:34 AM EDT
Completed Phase 2 Interventional

Dexamethasone in Cryptococcal Meningitis

NCT00000776
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Flucytosine, Fluconazole, Amphotericin B, Dexamethasone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
13
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 2, 2026, 4:34 AM EDT
Completed No phase listed Observational

A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients With Persistent Fever and Neutropenia

NCT00008840
View directory record Official record
Conditions
Neutropenia
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
866 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 2, 2026, 4:34 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections.

NCT04018417
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy
Interventions
Amphotericin B
Drug
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 2, 2026, 4:34 AM EDT
Completed Phase 3 Interventional Results available

Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)

NCT00750737
View directory record Official record
Conditions
Invasive Fungal Infections, Hematologic Malignancies
Interventions
Posaconazole, ABLC
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Sep 2, 2026, 4:34 AM EDT
Not yet recruiting Phase 3 Interventional

Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)

NCT07261150
View directory record Official record
Conditions
Histoplasmosis
Interventions
LAmB B, Posaconazole, World Health Organization (WHO)-recommended SOC, WHO-recommended SOC Itraconazole
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 2, 2026, 4:34 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group

NCT00634166
View directory record Official record
Conditions
Burns
Interventions
Sulfamylon® For 5 % Topical Solution, Topical Antimicrobial/Antifungal Medications
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
3 Months and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
9
States / cities
Mobile, Alabama • Redlands, California • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Sep 2, 2026, 4:34 AM EDT
Completed Phase 3 Interventional

A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections

NCT00002277
View directory record Official record
Conditions
Mycoses, HIV Infections
Interventions
Fluconazole, Amphotericin B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Results available

Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections

NCT00418951
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Voriconazole, Liposomal amphotericin B
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Sep 2, 2026, 4:34 AM EDT
Completed Phase 2 Interventional

Subjects With Non-Healing Venous Leg Ulcers Treated With Standard Care Plus Cryopreserved Human Umbilical Cord (TTAX01)

NCT03818828
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
TTAX01, Profore Compression Therapy, Cadexomer Iodine dressing
Biological · Other
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Carlsbad, California • Sylmar, California • North Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 2, 2026, 4:34 AM EDT
Completed Not applicable Interventional

A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

NCT00002068
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Fluconazole, Amphotericin B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Wilmington, Delaware • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 4:34 AM EDT
Completed Not applicable Interventional

Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients

NCT00002041
View directory record Official record
Conditions
Candidiasis, Esophageal, HIV Infections
Interventions
Amphotericin B
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 1, 2007 · Synced Sep 2, 2026, 4:34 AM EDT
Completed Phase 2Phase 3 Interventional

A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).

NCT00037206
View directory record Official record
Conditions
Aspergillosis
Interventions
Anidulafungin, VER002
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Sep 2, 2026, 4:34 AM EDT
Completed Phase 2 Interventional Results available

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study

NCT00419770
View directory record Official record
Conditions
Mucormycosis
Interventions
deferasirox, Placebo, Liposomal amphotericin B
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
7
States / cities
Duarte, California • San Francisco, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 2, 2026, 4:34 AM EDT
Not yet recruiting Phase 3 Interventional

Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

NCT06525389
View directory record Official record
Conditions
Talaromycosis
Interventions
Liposomal Amphotericin B (LAmB), Flucytosine (5FC), Flucytosine (5FC) placebo pill, Deoxycholate Amphotericin B (DAmB)
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 2, 2026, 4:34 AM EDT
Completed Phase 3 Interventional

A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis

NCT00002159
View directory record Official record
Conditions
HIV Infections, Histoplasmosis, Blastomycosis
Interventions
Itraconazole, Amphotericin B
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 4:34 AM EDT
Completed Phase 3 Interventional

Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer

NCT00002742
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
amphotericin B deoxycholate, nystatin
Drug
Lead sponsor
Aronex Pharmaceuticals
Industry
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
59
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Sep 2, 2026, 4:34 AM EDT
Completed Phase 3 Interventional

Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis

NCT00001646
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Aspergillosis, HIV Infections, Immunologic Deficiency Syndromes, Neutropenia
Interventions
Voriconazole, Amphotericin B
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 4:34 AM EDT
Completed Not applicable Interventional

A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis

NCT00002305
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Flucytosine, Fluconazole, Amphotericin B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 4:34 AM EDT
Completed Phase 3 Interventional

Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia

NCT00106288
View directory record Official record
Conditions
Candidiasis
Interventions
Micafungin, Liposomal Amphotericin B
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
Not listed
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
27
States / cities
Birmingham, Alabama • Orange, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Sep 2, 2026, 4:34 AM EDT
Completed Not applicable Interventional

Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome

NCT00002019
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Amphotericin B, Lipid-based, Amphotericin B
Drug
Lead sponsor
Liposome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
Torrance, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 4:34 AM EDT
Completed No phase listed Observational

PEACE: Pediatric Antifungal Comparative Effectiveness

NCT01869829
View directory record Official record
Conditions
Pediatric Invasive Candidiasis
Interventions
Observational antifungal therapy
Drug
Lead sponsor
Duke University
Other
Eligibility
120 Days to 18 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
27
States / cities
Little Rock, Arkansas • Orange, California • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Sep 2, 2026, 4:34 AM EDT